Navigation Links
Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
Date:5/6/2008

), p<0.0001. Furthermore, over the 24-month treatment period, relapse occurred in 16.5 percent of patients treated with RLAI and 31.3 percent in the quetiapine treatment arm.(6)

Both RLAI and quetiapine had generally comparable safety profiles. Extrapyramidal symptoms (EPS) attributed to medication were observed in 10 percent of the patients receiving RLAI and in six percent of the patients in the quetiapine group. Weight gain was observed in both treatment arms with no statistically significant differences in changes in body weight or BMI versus baseline (seven percent weight gain for RLAI versus 6.2 percent for quetiapine). Potentially prolactin-related adverse events were observed in 16.7 percent of the patients in the RLAI arm and in three percent of patients in the quetiapine arm.

Reasons for withdrawing from the study, other than relapse, were equivalent in both treatment groups except that more withdrawals due to non-compliance/refusing injection were reported for RLAI (three percent) than quetiapine (one percent). The most common serious adverse events were psychiatric symptoms (15 percent with RLAI and 18 percent with quetiapine). Death occurred in three patients treated with RLAI and two with quetiapine. None of the deaths were considered to be possibly or probably related to study drug.

The study was sponsored by Janssen-Cilag, Medical Affairs EMEA.

Separately, an interim analysis from a two-year U.S. observational study also presented today at APA showed patients taking RLAI had significantly improved functioning within three months after starting treatment. That study enrolled 532 patients from 66 community health centers and Veterans Affairs centers in the United States. Data collection occurred at baseline (month 0) and then every three months up to the two years. At the time of this interim analysis, 107 patients had completed the full two-year period.(7)

The U.S. interim analysis showed an overall significant impro
'/>"/>

SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Data Show High Frequency of Medical Claims for Gastrointestinal Events by Patients on Antiplatelet Therapy
2. Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
5. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
6. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
7. Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients, According to VentriPoint Diagnostics
8. Gene Therapy Improves Vision in Patients with Congenital Retinal Disease
9. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
10. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
(Date:7/10/2014)... CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of $0.275 (27.5 cents) per share on the ... 2014, to holders of record on July 21, 2014. ... dedicated to helping people on their path to better health ... United States . Through the company,s more than 7,600 ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Polio is history ... places like Afghanistan, Nigeria and Pakistan. Giving vaccinated children ... their immunity and help eradicate the highly infectious disease, ... is highly effective, immunity wanes as early as a ... be infected and contribute to the spread of the ...
(Date:7/11/2014)... breast cancer patients, the era of personalized medicine may ... by USC Stem Cell researcher Min Yu and scientists ... In a July 11 study in Science , ... cancer cells circulating through the blood streams of six ... "seeds" of metastasis, which travel to and establish secondary ...
(Date:7/11/2014)... FL (PRWEB) July 11, 2014 American ... on RFD-TV, next Tuesday, July 15, 2014, at 8:30 ... Sunbelt's line of proprietary products, which are designed and ... crops. Audiences will learn how these products help the ... environment in which it is grown. , The show ...
(Date:7/11/2014)... Shoulder instability is a common injury in ... has not been regularly determined following surgery. A new ... Medicine’s ( AOSSM ) Annual Meeting today details that ... no matter what the stabilization procedure (open vs. arthroscopic). ... to play following shoulder stabilization surgery. Age, number of ...
(Date:7/11/2014)... Anterior Cruciate Ligament (ACL) reconstructions occur more ... material used to create a new ligament may determine ... presenting their work today at the Annual Meeting of ... ). , “Our study results highlight that ... a donor) fail more frequently than using autografts (tissue ...
Breaking Medicine News(10 mins):Health News:Researchers Assess New Way to Boost Polio Immunity 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... , SINGAPORE, Nov. 16 /PRNewswire-Asia/ ... Malaysia grew steadily in the first half of 2009 with,total ... promotions from major Contact Lens manufacturers. Positive sales,data showing a ... view of an economic recovery that is being led by ...
... ... Critical Strategies for Successful Interactions Between Life Science Companies and Health Care Providers ... ... sales enablement and IT consulting company, today announced that UCB, a global biopharmaceutical ...
... ... Kids who Wear Ankle-Foot Orthoses (AFOs) , ... Westchester, NY (PRWEB) November 16, 2009 -- Ross Daniel Adaptive Apparel ... and the launch of “Cool Clothes for Toes,” the first creatively styled sock line for ...
... NANJING, China, Nov. 16 /PRNewswire-Asia/ -- Simcere Pharmaceutical ... pharmaceutical company,specializing in the development, manufacturing, and marketing of branded,generic and ... ended September 30, 2009. , , Highlights, ... the third, quarter of 2009, ...
... , Study highlights: , In patients with or ... treated with statins to < 100mg/dL but low HDL (good ... LDL further. , Patients were randomized to the addition of ... LDL cholesterol). Plaque buildup in the lining of the ...
... ... to begin the drug registration process in Brazil and Colombia for its over-the-counter pain ... for the treatment of moderate to severe (Stage 2) chronic pain. , ... Plantation, FL (Vocus) November 15, ...
Cached Medicine News:Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 3Health News:Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 12Health News:American Heart Association Late Breaking Clinical Trial Report: In Patients on Statins, Raising Good Cholesterol with Niacin, but not Reducing Bad Cholesterol with Ezetimibe, Decreases Plaque Build-Up 2Health News:American Heart Association Late Breaking Clinical Trial Report: In Patients on Statins, Raising Good Cholesterol with Niacin, but not Reducing Bad Cholesterol with Ezetimibe, Decreases Plaque Build-Up 3Health News:American Heart Association Late Breaking Clinical Trial Report: In Patients on Statins, Raising Good Cholesterol with Niacin, but not Reducing Bad Cholesterol with Ezetimibe, Decreases Plaque Build-Up 4Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 3Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 4
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
Medicine Products: